Saturday, October 31, 2026

NIO Stock Over 5% Up So Far Today as Electric-Car Demand in China Picks Up

ViaNews Editorial Team

November 19, 2020

NIO Stock Over 5% Up So Far Today as Electric-Car Demand in China Picks Up
According to Bloomberg Quint on Tue Nov 17, "Nio Loss Narrows After Electric-Car Demand in China Picks Up." NIO has been somewhat immune to the crisis with the shares jumping 5.79% to $47.67 at 13:05 EST on Thursday. The New York Stock Exchange is dropping 0.19% to $13782.5, on what seems, up until now, an all-around negative trading session on The New York Stock Exchange. According to yesterday's article on Bloomberg Quint, "Electric-SUV Maker Nio to Add Sedans as Tesla Rivalry Heats Up." Chinese EV maker NIO is accelerating too fast. According to yesterday's article on The Wall Street Journal, "Just a year ago, Nio was struggling for survival." NIO's last close was $45.06, under its 52-week high of $54.2. NIO's sales growth is 113.1% for the ongoing quarter and 263.3% for the next. The company's growth estimates for the ongoing quarter and the next are 64.1% and 47.8%, respectively. NIO's stock is valued at $47.67 at 13:05 EST, way under its 52-week high of $54.2 and way above its 52-week low of $1.82. NIO's worth is way above its 50 day moving average of $31.37 and way above its 200 day moving average of $16.46.
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com